NTRA - Should You Buy These 2 Prenatal Testing Stocks?
By 2023, an estimated 3.5 million reproductive genetic tests will be performed annually in the United States. Driving the expanded use of these tests are updated guidelines from the American College of Obstetricians and Gynecologists and the American College of Medical Genetics. Can investors capitalize on this growing trend?
Image Source: Getty Images.
Approximately 4.2 million pregnancies occur annually in the United States. Of those, 0.8 million are classified as high-risk, and the remaining 3.4 million as average risk. Diagnostic companies, big and small, have developed tests to look for potential genetic conditions in both the carrier (parent) and the unborn child. Myriad Genetics (NASDAQ: MYGN) and Natera (NASDAQ: NTRA) lead the field in the development and marketing of diagnostic tests for reproductive health.